<DOC>
	<DOCNO>NCT00706420</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness islet cell transplantation alone ( ITA ) patient difficult control type I diabetes . Difficult control type 1 diabetes define wide swing blood glucose disrupt patient 's life result frequent episode low blood glucose despite proper use standard insulin therapy frequent blood glucose monitoring .</brief_summary>
	<brief_title>Islet Transplantation Alone ( ITA ) Patients With Difficult Control Type I Diabetes Mellitus Using Glucocorticoid-free Immunosuppressive Regimen</brief_title>
	<detailed_description>Type 1 diabetes associate damage specific cell subtype pancreatic islet ( cluster cell pancreas produce insulin metabolic hormone ) , make patient depend outside source insulin . Despite insulin treatment , type 1 diabetes mellitus cause significant risk long-term problem , include damage heart , blood vessel , nerve , eye kidney . The result recent research study suggest complication cause poor glucose control . Transplantation islets offer prospect good glycemic ( blood glucose ) control without major surgical risk associate whole pancreas transplant may result need insulin injection . In 2000 , group investigator Edmonton , Canada show islet transplantation use combination anti-rejection drug help prevent rejection transplant islet effective eliminate insulin intake 7 subject follow 20 month . After 5 year , 60 patient transplant Edmonton 1 10 remain insulin . This study perform confirm result Edmonton study see islet transplantation alone ( ITA ) safe effective way treat subject type 1 diabetes . This study use additional medication vitamin supplement include original Edmonton study . We hope improve long-term outcome islet transplantation .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Difficult control Type 1 diabetes mellitus ( define ) . Documentation negative basal stimulate Cpeptide ( basal level &lt; 0.2 ng/ml IV administration 1 mg glucagon , glucagon stimulate Cpeptide &lt; 0.8 ng/ml ) diagnosis diabetes least 5 year . When possible , patient evaluate continuous glucose monitoring ( GlucoseSensor Â® ) determine frequency extent hypo hyperglycemic episode . No evidence chronic renal failure significant proteinuria ( serum creatinine &lt; 1.6 mg/dl , creatinine clearance &gt; 80 ml/min , albumin excretion &lt; /= 300 mg/24 hr ) . No evidence liver disease ( liver enzymes &lt; twice upper limit normal ALT AST , bilirubin &lt; 2 mg/dl , albumin &gt; 3.5 g/dl , PT PTT &lt; /= 1.1 x upper limit normal ) . Frequent episodes symptomatic hypoglycemia ( i.e . loss consciousness , headache , anxiety , irritability , tremble , sweat ) per week , document hypoglycemic unawareness ( i.e . adrenergic and/or neurogenic symptom blood glucose &lt; 54 mg/dl ) two time past two month , hypoglycemic episode require assistance another person per month hospitalization past 20 month . Ability comply posttransplant regimen , include immunosuppression , insulin pump therapy metabolic testing . Patients require perform selfmonitoring blood glucose minimum four time daily , provide complete record blood glucose level insulin dos . Ability give inform consent . Age great equal 18 year less equal 65 year . Significant liver disease ( include elevation liver enzymes &gt; twice upper limit normal ALT AST , bilirubin &gt; 2 mg/dl , albumin &lt; 3.5 g/dl , liver mass , portal vein thrombosis , evidence portal hypertension , significant , untreated gallbladder disease ( i.e . gallstone ) . Significant cardiovascular disease , include noncorrectable coronary artery disease ejection fraction &lt; 50 % and/or recent myocardial infarction ( within last 12 month ) ; extensive peripheral vascular disease correctable surgery untreated proliferative retinopathy . Recent unresolved acute infection , chronic infection , include tuberculosis , HIV , HBV , HCV , CMV positive skin test TB . Any history malignancy , except squamous basal skin cancer situ cancer cervix . Recent history noncompliance , inability demonstrate capacity comply strict blood glycemic control insulin pump therapy . Psychiatric illness untreated , likely interfere significantly transplantation despite treatment . Presence preform antibody panel reactive antibody screen &gt; 20 % . Body mass index ( BMI ) great 30 . Age le 18 year great 65 year . Presence chronic disease must chronically treat one follow medication : glucocorticoid , diazoxide , bumetanide , haloperidol , chlorpromazine , desipramine , doxepin , imipramine , isoproterenol , levodopa , morphine , Lasparaginase , cyclophosphamide , isoniazid , heparin , nalidixic acid , agent may adversely influence glycemic control may confound interpretation Graft Success posttransplant . Pregnant woman , woman intend future pregnancy , woman reproductive potential unable unwilling follow effective contraceptive measure duration immunosuppressive therapy , woman presently breast feed ineligible due unknown effect drug fetus nursing infant . Active alcohol substance abuse , include cigarette smoking ( must abstinent &gt; 3 month ) . Hyperlipidemia ( total cholesterol &gt; 260 mg/dl , LDL &gt; 130 mg/dl , and/or triglyceride &gt; 300 mg/dl ) despite appropriate treatment . Anemia ( Hgb &lt; 12 g/dl ) hematologic disorder require medical attention . Increased risk bleeding ( platelet count &lt; 80,000 ; INR &gt; 1.5 ) , chronic hemostasis disorder , treatment chronic anticoagulant therapy ( i.e . heparin warfarin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Islet Transplantation Alone</keyword>
	<keyword>Glucocorticoid-free Immunosuppressive Regimen</keyword>
</DOC>